Generic drug

Introduction The market for generic drugs has been increasing recently, with a large share of total prescriptions being dispensed in the United States. At the wholesale level, the generic drug market has typically been viewed as very competitive, such that prices approach marginal costs1. Therefore the availability of generic drugs is perceived as beneficial to consumers who have to pay for these drugs. However, at the retail level, generic drug prices seem to exceed marginal cost even by a wide

and the generic drug sector of the healthcare industry is no different. The alignment, however, is an anomaly to schools of thought that we are accustomed to. Demand for generic drugs in the United States is unquestionably high. Designed to help offer lower cost options for medications, this market provides financial relief for individuals who need medication to help with a common virus or a life-threatening illness. The disparity of medication costs can be significant for generics, with estimates

brand and generic drugs through their labeling. Further, the Court has grappled with determining which channels are available to consumers when a drug manufacturer breaches their duty. With the swarm of inconsistencies set forth by the Court in each newly decided case, and a proposed rule regarding generic “changes being effected” preparing to take effect Fall 2015, it is difficult to determine if the necessary guidance for drug manufacturers and consumers has been provided. Pharmaceutical drug

growth in generic drugs has slowed considerably from 42% in 2011 to 10% currently. IMS Health predicts the growth to maximize at 90% of the prescription market (Salazar, 2015). Though there is not much room between generic drugs currently representing 83% of prescription drugs and the predicted 90% maximum, the next twelve months appear a safe investment period for the generic drug industry when considering the currently growth rate. Many factors influence success in the generic drug industry;

INTRODUCTION: A Generic drug (generics) is a drug product that is comparable to a brand/reference-listed drug product in dosage form, strength, quality and performance characteristics, and intended use. These are produced and distributed without patent protection. The Generic drug must contain the same active ingredients as the original formulation. Generic drugs are identical or within an acceptable bioequivalent range to the brand name counterpart with respect to pharmacokinetic and pharmacodynamic

competition between generic and name-brand drugs, these drugs show very slight differences in ability while they have a large difference in price. The FDA is in charge of overseeing the creation of these generic and name brand drugs. Too much diversity in their results is unacceptable to FDA so they keep a close watch on the makeup and effectiveness of the drugs and how they impact the human body. Along with the differences in their chemical makeups shown by the results of each drug there are the social

Harling Ms. Wenzler Freshman Honors English 7 April 2015 Generic Drugs: The Rising Cost “Historically, generic drugs have long been considered a vital weapon in the fight to contain soaring health care costs. But in the past years, the price of many generics is disconcertingly moving in the wrong direction, drawing the attention of Congress and pricing the wallets of consumers as well as pharmacies and insurers” (Hirst). Generic drugs were introduced to help combat the rising cost of health care

Currently, generic drug plays an important role in the pharmaceutical industry. A generic drug is a type of drugs which are nearly a copy of brand drug. When a brand drug is approved, the branded company will have drug patents to protect the new drugs from being copied for twenty years. Generic manufacturers may copy the drug formula and change some of the ingredients of the drugs and sell them after twenty years. Generic drugs have now been commonly used to be prescribed to patients (Razmaria &

switching from brand name drugs to generic medications, discussing potential alternative medications that are less expensive with healthcare providers, and rallying lawmaker to change current laws to restrict the amount pharmaceutical companies can charge for medications. Generic Drugs In 2012, the Food and Drug Administration (FDA) reported that in 2004, the “average price for generic prescription drug was $28.74, while the average price of a brand-name prescription drug was $96.01.” The FDA recognizes

Generic Drug Profile - Salbutamol New Zealand trade names: Ventolin, Respigen, Salamol, Asthalin, Salapin and Broncolin. Drug Class: Therapeutic class: bronchodilator. Pharmacologic class: sympathomimetic (stimulates the sympathetic nervous system). It is also classified as a SABA (short acting β2-agonist). Formulations: The most common administration is by inhalation of a pressurised metered dose aerosol. Inhalation of Salbutamol directly reaches the lungs and acts rapidly with fewer side effects